The Prostate Cancer Foundation has funded 24 young investigators with $225,000 each over three years. Among them is Barry Taylor of Memorial Sloan-Kettering Cancer Center for his proposal on looking for genomic markers that would predict whether prostate cancer patients would develop an aggressive form of the disease.
The award follows on Taylor's work on MSKCC's Prostate Oncogenome Project, which identified patterns of copy number alterations in men who were highly likely to develop castrate-resistant disease. He will now continue that work to determine the clinical importance and pathogenicity of copy number alterations in prostate cancer with the goal of developing a diagnostic test that could distinguish between high-risk and low-risk patients.
Interleukin Genetics has appointed Lynn Doucette-Stamm to vice president of development, a newly created position. In the role, she will supervise the company's clinical studies and development of genetic tests.
Most recently, Doucette-Stamm served as vice president of business development at Agencourt Bioscience. Previously she served as director of genomics and vice president and general manager of the Genome Vision Services Unit at Genome Therapeutics. In that position, she was responsible for managing large teams working on the Human Genome Project as well as commercial sequencing programs. She also established the company's genomics business unit.
Doucette-Stamm holds a BS in biology from McMaster University and a PhD in genetics from Cornell University.